MASP2

Transcenta Received IND Clearance from FDA for Its Best-In-Class MASP2 Targeting Antibody TST004 for the Treatment of IgA Nephropathy

Retrieved on: 
Mercredi, octobre 5, 2022
News, Therapy, Chronic kidney disease, ISN, IND, IgA nephropathy, China Media Group Headquarters, ICB, HKEX, Patient, Social conditioning, Research, Thrombotic microangiopathy, Inflammation, Process, Food, MASP2, Discovery, Food and Drug Administration, Mab, Nature, TMA, Immunoglobulin A, Environment, Time-invariant system, Headquarters, FDA, Suzhou Industrial Park, Fine chemical, Vaccine, Pharmaceutical industry

Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.

Key Points: 
  • Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.
  • TST004 is a humanized mAb targeting mannose-binding protein-associated serine protease 2 (MASP2) and designed to prevent the inflammation and tissue damage mediated by lectin pathway complement activation.
  • TST004 is a humanized mAb targeting mannose-binding protein-associated serine protease 2 (MASP2) and designed to prevent the lectin pathway complement-mediated inflammation.
  • Transcenta discovered and developed TST004 in-house and plan to develop TST004 for IgA nephropathy (IgAN), a highly prevalent chronic kidney disease with very limited treatment options.

Transcenta was Selected to Present the Preclinical Data of TST004 at the 2022 ISN Frontiers Meetings of Complement Related Kidney Diseases

Retrieved on: 
Mardi, juin 28, 2022
IgA nephropathy, ICB, Patient, CEO, Research, China Media Group Headquarters, Time-invariant system, Headquarters, Disease, Thrombotic microangiopathy, Immunoglobulin A, Inflammation, Poster, Mab, Social conditioning, Therapy, NHP, Clinical trial, Environment, ISN, Discovery, Suzhou Industrial Park, Chronic kidney disease, TMA, HKEX, MASP2, Process, News, Nature, Fine chemical, Vaccine, Pharmaceutical industry, List of commonly used taxonomic affixes

Studies have shown that lectin pathway activation contributes to multiple human diseases such as immunoglobulin A nephropathy (IgAN), hematopoietic stem-cell transplantationassociated thrombotic microangiopathy (HSCT-TMA).

Key Points: 
  • Studies have shown that lectin pathway activation contributes to multiple human diseases such as immunoglobulin A nephropathy (IgAN), hematopoietic stem-cell transplantationassociated thrombotic microangiopathy (HSCT-TMA).
  • Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.
  • Dr. Xueming Qian presented the poster which highlighted the following preclinical data:
    TST004 binds to MASP2 selectively in high affinity.
  • TST004 showed more potent in vitro and in vivo blocking activities for the MASP2 dependent lectin complement pathway than benchmark.

Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial

Retrieved on: 
Mardi, mars 23, 2021
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Complement system, Medical specialties, Organ systems, Immunology, Immune system, Lectins, Blood proteins, MASP2, Lectin pathway, Mannan-binding lectin-associated serine protease-2, Mannan-binding lectin, Mannans, Omeros Corporation, Narsoplimab, the I-SPY TRIALS, Quantum Leap Healthcare Collaborative

Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month.
  • The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative.
  • The pulmonary and critical care investigators leading the I-SPY COVID Trial uniformly endorsed narsoplimab and made it a high-priority candidate for the trial.
  • Narsoplimab is Omeros lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement.

Omeros Hires Nadia Dac as Chief Commercial Officer

Retrieved on: 
Mardi, janvier 26, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical trials, Complement system, Branches of biology, Proteins, Mannan-binding lectin-associated serine protease-2, MASP2, Mannan-binding lectin, Omeros, Lundbeck

Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer.
  • In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial launch of narsoplimab, the companys mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor.
  • Were pleased that Nadia has joined our senior leadership team, said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.
  • She joins Omeros from her most recent role as the chief commercial officer at Alder Pharmaceuticals where she built the commercial team to launch Vyepti in the migraine prevention market, which later was acquired by Lundbeck.

Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit

Retrieved on: 
Vendredi, octobre 16, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Immune system, Branches of biology, Proteins, Lectins, Mannan-binding lectin, Complement system, Alternative complement pathway, Biology, MASP1, MASP2, OMS906, Omeros Corporation

Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit.
  • OMS906 is the companys lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement systems alternative pathway.
  • Data also showed that lowest levels of detectable mature CFD correlated with complete inactivation of the alternative pathway.
  • Omeros expects OMS906 to have broad application in conditions involving inflammation and tissue damage as well as disorders associated with dysregulation of the alternative pathway.

Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients

Retrieved on: 
Jeudi, septembre 3, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Organ systems, Proteins, Immune system, Lectins, Blood proteins, Lectin pathway, MASP2, Mannan-binding lectin-associated serine protease-2, Mannan-binding lectin, Coronavirus disease, Complement system, Narsoplimab, Omeros Corporation

The panel discussed the emerging evidence that endothelial injury and the activation of the lectin pathway of complement are central drivers of the acute respiratory distress syndrome (ARDS) and thrombosis seen in critically ill COVID-19 patients.

Key Points: 
  • The panel discussed the emerging evidence that endothelial injury and the activation of the lectin pathway of complement are central drivers of the acute respiratory distress syndrome (ARDS) and thrombosis seen in critically ill COVID-19 patients.
  • Narsoplimab, Omeros investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key effector of the lectin pathway of complement, was identified as a potentially highly effective therapy to treat critically ill COVID-19 patients.
  • Omeros previously announced positive results from the treatment with narsoplimab of six critically ill COVID-19 patients under a compassionate use protocol.
  • All patients initially required mechanical ventilation and, following treatment with narsoplimab, all recovered, survived and were discharged from the hospital.

Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome

Retrieved on: 
Lundi, août 10, 2020
Research, General Health, Pharmaceutical, Infectious diseases, Hospitals, Other Manufacturing, Genetics, Clinical trials, Science, Stem cells, Manufacturing, Health, Medical specialties, Branches of biology, Clinical medicine, Hematology, Complement system, Acquired hemolytic anemia, Histopathology, Thrombotic microangiopathy, Mannan-binding lectin-associated serine protease-2, MASP2, Hematopoietic stem cell transplantation, Acute respiratory distress syndrome, Narsoplimab, Omeros Corporation

Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), in the treatment of COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe and life-threatening symptom of COVID-19.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), in the treatment of COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe and life-threatening symptom of COVID-19.
  • Narsoplimab also has been evaluated in patients in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), another often-lethal thrombotic disorder associated with endothelial damage.
  • In its pivotal HSCT-TMA trial, narsoplimab-treated patients demonstrated marked improvement in laboratory and clinical endpoints and unexpected survival.
  • Omeros management will host a webcast and conference call to present the results of a compassionate-use study evaluating narsoplimab in the treatment of COVID-19 patients with ARDS.

Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System’s Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria

Retrieved on: 
Mercredi, septembre 25, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Medical specialties, Organ systems, Medicine, Kidney diseases, Immune system, Blood disorders, Lectins, MASP2, Mannan-binding lectin-associated serine protease-2, Mannan-binding lectin, IgA nephropathy, Atypical hemolytic uremic syndrome

Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria (i.e., high levels of plasma proteins in the urine) and inflammation.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria (i.e., high levels of plasma proteins in the urine) and inflammation.
  • The article, published in Frontiers in Immunology and entitled Absence of the Lectin Activation Pathway of Complement Ameliorates Proteinuria-Induced Renal Injury, can be accessed online at https://www.frontiersin.org/articles/10.3389/fimmu.2019.02238/full .
  • Both MASP-2-deficient and MASP-2 inhibitor-treated animals demonstrated marked renoprotection and reduction in inflammation from proteinuria with significantly less tubulointerstitial injury when compared to isotype antibodytreated controls.
  • Omeros lead MASP-2 inhibitor narsoplimab is in Phase 3 clinical programs for the treatment of IgA nephropathy and of atypical hemolytic uremic syndrome.

Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab

Retrieved on: 
Mercredi, juillet 31, 2019
Biotechnology, Health, Pharmaceutical, Optical, Oncology, Stem cells, Research, General Health, Genetics, Science, Proteins, Complement system, Branches of biology, Mannan-binding lectin-associated serine protease-2, MASP2, Mannan-binding lectin, Lonza, Mannan, Lonza, Omeros Corporation

Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), also referred to as OMS721.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), also referred to as OMS721.
  • Omeros and Lonza have successfully partnered under a multi-year manufacturing agreement for the clinical supply of narsoplimab.
  • The new multi-year agreement secures a source of commercial quantities of narsoplimab for use following anticipated regulatory approvals.
  • Lonza has worked closely with us to accelerate the timing of our BLA and MAA submissions, and were confident in Lonzas ability to produce and maintain the highest quality commercial supply of narsoplimab.